Table 3.

Frequency of antiretroviral drug use and viral suppression at screening and at 12 months by gender identity.

	TGW (N = 24)	MSM (N = 39)	P-value
ARV drug use
ARV drug use at screening	8/24 (33.3%)	10/39 (25.6%)	0.511a
ARV drug use at 12 months	15/24 (62.5%)	23/39 (59.0%)	0.781a
Increase in ARV drug use	1.9-fold	2.3-fold	0.774b
Viral suppression
Virally suppressed at screening	6/24 (25.0%)	8/39 (20.5%)	0.677a
Virally suppressed at 12 months	15/24 (62.5%)	22/39 (56.4%)	0.634a
Increase in viral suppression	2.5-fold	2.8-fold	0.997b

The table shows the frequency of ARV drug use and viral suppression at screening and 12 months by gender identity. The fold change increase in ARV drug use and viral suppression during the 12-month follow-up period is also shown.

Abbreviations: TGW, transgender women; MSM, men who have sex with men; and ARV, antiretroviral.

^aChi-Square p-value.

^bP-value from logistic regression.